ScreeningPort is planned to be at the heart of an international network. Although it is still at an early stage, a number of European research institutes have already been tied in. Among others, the Swiss Federal Institute of Technology (ETH Zurich) and the Vienna-based Institute of Molecular Biotechnology of the Austrian Academy of Sciences have signed letters of intent.
The ScreeningPort project was initiated by Evotec AG, a leading drug discovery and development company, bringing in its extensive expertise. It was implemented by Norgenta GmbH, the north German life science agency that promotes the structural development of life sciences in the federal states of Hamburg and Schleswig-Holstein.
Other partners are also raring to go, such as c.a.r.u.s. IT AG, a company specialised in high-performance data management solutions for life sciences.
Thomas Rachel, member of the German federal parliament and parliamentary secretary of state at the German Federal Ministry of Education and Research:
"ScreeningPort is an important element to close the gap between basic research and the commercial development of new therapeutics. Therefore the Federal Ministry of Education and Research has decided to financially support, as part of its Pharmaceuticals Initiative for Germany campaign, the establishment of the ScreeningPort and initial pilot projects in screening. Total funding of more than EUR 800 million will be provided by 2011 under this initiative which is aimed at accelerating the development of innovative therapeutics for patients."
Senator Gunnar Uldall, Head of the State Ministry of Economic and Labour Affairs, City of Hamburg:
"By funding and implementing this project, we continue and further
complement our successful cluster policy for the life sciences in northern
Germany. The new ScreeningPort provides Hamburg with the opportunity to
become a leading European centre of moder
|SOURCE Evotec AG|
Copyright©2007 PR Newswire.
All rights reserved